Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On November 23, 2020, Codiak BioSciences, a clinical-stage company developing exosome-based therapeutics, announced that Douglas E. Williams, Ph.D., its President and CEO, will speak at the Evercore ISI 3rd Annual HealthCONx Conference. The fireside chat is scheduled for December 2 at 4:45 p.m. ET. A live webcast will be available on Codiak's website, with an archived replay accessible for 90 days. Codiak aims to revolutionize treatment for various diseases through its innovative engEx Platform, creating novel exosome therapeutic candidates.
Details
News Market Reaction – CDAK
The recorded move for CDAK in the trading session of this news was +7.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference. Details are as follows:
Evercore ISI 3rd Annual HealthCONx Conference
Date: Wednesday, December 2
Time: 4:45 p.m. ET
A live webcast of the fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. An archived replay will be available for approximately 90 days following the fireside chat.
About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Media Contact
Lindy Devereux
Scient PR
T: 646-515-5730
E: media@codiakbio.com
Investor Contact
Christine Labaree
Evergreen Communications
T: 650-600-1697
E: investor@codiakbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.